Last reviewed · How we verify
AZLOCILLIN
AZLOCILLIN is a small molecule antibiotic developed by BAYER PHARMACEUTICALS CORP, which is still owned by the same company. It was approved by the FDA in 1982 for various bacterial infections, including aspiration pneumonia and bacterial septicemia. AZLOCILLIN is classified as an azlocillin, a type of beta-lactam antibiotic. It is off-patent and has a single generic manufacturer. Key safety considerations include its short half-life of 1.2 hours and low bioavailability of 0%.
At a glance
| Generic name | AZLOCILLIN |
|---|---|
| Sponsor | Bayer Pharmaceuticals Corp |
| Drug class | azlocillin |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Aspiration pneumonia
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial septicemia
- Enterobacter Pneumonia
- Haemophilus influenzae pneumonia
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Pneumonia due to Escherichia coli
- Pneumonia due to Pseudomonas
- Urinary tract infectious disease
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZLOCILLIN CI brief — competitive landscape report
- AZLOCILLIN updates RSS · CI watch RSS
- Bayer Pharmaceuticals Corp portfolio CI